Group One Trading’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-130,300
Closed -$13.3M 8561
2023
Q2
$13.3M Sell
130,300
-1,100
-0.8% -$104K 0.04% 382
2023
Q1
$11.9M Buy
131,400
+103,500
+371% +$6.07M 0.04% 390
2022
Q4
$1.06M Sell
27,900
-113,200
-80% -$3.9M ﹤0.01% 2361
2022
Q3
$3.55M Buy
141,100
+132,200
+1,485% +$3.66M 0.01% 1446
2022
Q2
$270K Sell
8,900
-33,600
-79% -$1M ﹤0.01% 4010
2022
Q1
$1.39M Buy
42,500
+23,200
+120% +$688K ﹤0.01% 2758
2021
Q4
$509K Sell
19,300
-29,000
-60% -$2.24M ﹤0.01% 4113
2021
Q3
$4.86M Sell
48,300
-5,600
-10% -$656K 0.01% 1718
2021
Q2
$7.63M Buy
53,900
+34,900
+184% +$3.94M 0.01% 1307
2021
Q1
$1.89M Buy
19,000
+18,100
+2,011% +$2.11M ﹤0.01% 2531
2020
Q4
$111K Sell
900
-1,200
-57% -$158K ﹤0.01% 4491
2020
Q3
$205K Sell
2,100
-9,400
-82% -$1.17M ﹤0.01% 3626
2020
Q2
$1.79M Sell
11,500
-44,300
-79% -$6.73M 0.01% 1547
2020
Q1
$8.05M Buy
55,800
+38,300
+219% +$7.39M 0.07% 328
2019
Q4
$3.58M Buy
17,500
+17,100
+4,275% +$3.12M 0.02% 883
2019
Q3
$32K Buy
+400
New +$33.9K ﹤0.01% 4188
2019
Q1
Sell
-3,200
Closed -$180K 5513
2018
Q4
$180K Sell
3,200
-100
-3% -$6.11K ﹤0.01% 2765
2018
Q3
$270K Buy
+3,300
New +$233K ﹤0.01% 2790
2018
Q2
Sell
-200
Closed -$4K 5587
2018
Q1
$4K Buy
+200
New +$5.15K ﹤0.01% 4566

Other funds holding RETA

Group One Trading's RETA Position: Q2 2023 in Review

Group One Trading sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 24,376 shares — an estimated $2.31M sold.

Group One Trading first reported a position in RETA in Q1 2018 and held it in 10 quarters. The position peaked at $2.22M in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

  • Group One Trading reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
  • Group One Trading sold 24,376 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $2.31M.
  • Group One Trading first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2018 and held it in 10 quarters.
  • Group One Trading's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.22M in Q1 2023.
  • 214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Group One Trading's 13F filing for Q2 2023, filed 9 Aug 2023.